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The immune system is unique in its dynamic interplay, and highly specialized cell types 
execute its diverse functions. A major goal of immunology research is to elucidate how the 
context-dependent crosstalk between different cell types and the orchestration of their 
functions enable protection against disease. Due to the plasticity of immune responses and 
their context-dependent pathophysiological states, interpreting them is inherently challenging. 
Thus, the immune system has been studied at various hierarchical levels - genomic, 
transcriptional, translational, cellular signaling process, cell heterogeneity, spatial, 
intercellular, and organismal - each of which forms its own specialized networks. The 
advancement of large-scale omics-technologies and automated bioinformatic analysis 
pipelines increased the number of high-throughput experiments, resulting in diverse datasets 
suitable for studying the immune system from a network perspective. As such, the versatile 
toolbox of mass spectrometry-based proteomics has become an integral part of modern 
systems immunology research enabling the analysis of expression levels of thousands of 
proteins within immune cells, their interaction partners, post-translational modifications, and 
localization. 
This thesis objectives were twofold: to advance the journey towards complete, accurate, and 
ubiquitous cell proteomes and to identify novel network connections that contribute to the 
understanding of immune responses. 
This thesis demonstrates that proteomics can generate high-quality and comprehensive 
proteome profiles not only form individual immune cell types but also from time-resolved 
immune responses as well as multicellular immune systems derived from primary human 
samples. The optimized quantitative shotgun proteomics workflow with three-hour gradients 
achieved an average of 7,500 quantified proteins per measurement. In total, this thesis 
provides over 200 immune cell proteomes, that collectively cover 70% of all immune-relevant 
signaling molecules, including transcription factors, adaptor molecules, cell surface receptors, 
and secreted molecules, making this the most comprehensive immune proteome resource to 
date. From this data, I constructed three different immune networks - (1) a functional 
intracellular transcriptome and proteome network of murine CD8 memory T cells, (2) an 
intracellular and time-resolved proteome and metabolome network of the human CD4 T cell 
immune response, and (3) an intra- and intercellular proteome and secretome network of the 
human hematopoietic system. Cell surface markers from these networks resulted in a new 
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functional classification of memory T cells that could potentially be used to evaluate 
vaccination studies. Furthermore, the metabolome-proteome network identified L-arginine as 
a critical metabolite during T cell activation, enhancing T cell survival and anti-tumor 
activity. This discovery may be used to boost the efficacy of adoptive T cell therapies. 
Finally, the hematopoietic cell-cell communication network revealed novel intercellular 
connections and serves as a healthy state reference map for future studies aimed at identifying 
activation and disease-specific extracellular signaling pathways that can be targeted by 
immunotherapies. 
Together, this thesis expanded the frontiers of quantitative mass spectrometry-based 
proteomics from few immune cell proteomes to system-wide protein-centric immune cell 
networks and provided the basis to understanding basic principles of intercellular signaling 
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1.1 The immune system 
1.1.1 Introduction to the immune system 
Immunology emerged from medical microbiology in the last quarter of the nineteenth century 
to a well established field in both basic and clinical research today1. Louis Pasteur’s germ 
theory and Robert Koch’s studies on infectious diseases introduced a paradigm shift that 
diseases not only arise from dysfunctional body cells but can also be caused by exogenous 
pathogens. It took another two major discoveries that coined the birth of immunology. Elias 
Metchnikoff found that white blood cells can engulf and destroy invading pathogens2, by a 
process called phagocytosis (Nobel Prize in Physiology or Medicine 1908) and Emil von 
Behring demonstrated that serum from infected animals can protect another animal from that 
disease (Nobel Prize in Physiology or Medicine 1901). These findings laid the basis for innate 
and acquired as well as cellular and humoral immunity, respectively. This two-class 
separation of the immune system was soon relaxed by Jules Bordet’s work on the interaction 
of complement and antibodies (Nobel Prize in Physiology or Medicine 1919), as well as the 
experiments of Almroth Wright3, who observed that antibodies can specifically facilitate 
phagocytosis of bacteria supporting the concept that the two arms of the immune system are 
highly intertwined. Furthermore, Paul Ehrlich’s proposed “horror autotoxicus” theory was 
questioned, and it became clear that aberrant antibody responses could lead to 
hypersensitivity reactions4, shown for example by Charles Richet’s research on anaphylaxis 
(Nobel Prize in 1913). During that time, other clinical immunology contributions such as the 
discovery of the ABO major blood group system5 (Landsteiner Nobel Prize in 1930) as well 
as immunochemistry discoveries such as the chemical structure of antibodies6,7 (Rodney 
Porter and Gerald Edelman Nobel Prize in 1972) lead to a deeper understanding of the 
immune system. Then the area of immunobiology started with the discovery of antibody-
producing B lymphocytes and immune regulating T lymphocytes8, which soon became 
established as responsible cells of acquired cellular and humoral immunity, respectively1. In 
parallel, the major histocompatibility complex (MHC) was discovered to be accountable for 
transplant rejections9 (Snell, Dausset and Benacerraf the Nobel Prize in 1980). These findings 
converged with the demonstration by Doherty and Zinkernagel that MHC molecules, besides 
transplant rejection, are also responsible for T-cell recognition of any type of antigen (Nobel 
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Prize in 1996). Many more important discoveries were made during that period that still shape 
our understanding of cellular immunity today. Besides cellular immunity, other eminent 
immunological questions were answered. For instance, Frank Macarlane Burnet and Peter 
Brian Medawar shed light on the immunological tolerance10,11 (Nobel Prize in 1960) and 
Susumu Tonegawa explained the mechanisms under 
 
 
Figure 1: History of immunology form serum therapy to checkpoint control (adapted from1). 
 
lying the huge diversity of antibody specificities12 (the Nobel Prize in 1987). The acquired 
immune response dominated immunobiology in the second half of the twentieth century, but 
this changed with the discoveries of pattern recognition receptors13,14 (Bruce Beutler and Jules 
Hoffmann Nobel Prize in 2011) and the major T cell instructor the dendritic cell15 (Ralph 
Steinman Nobel Prize in 2011). Their work showed that innate immunity serves the immune 
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response from beginning to the end by first stimulating T cells through antigen presentation 
and second acting as professional phagocytes to clear invading pathogens. The extensive 
knowledge accumulated by basic immunology research was and is tightly linked to clinical 
applications. This can be seen by the first Nobel Prize for serum therapy awarded to Emil 
Behring, or by the production of monoclonal antibodies (Nobel Prize in 1984) that paved the 
way for cytokine-blocking immunotherapies against chronic inflammatory diseases16, or by 
the latest Nobel Prize in 2018 for the discovery of cancer therapy by inhibition of negative 
immune regulation (Figure 1)17. 
This short historical summary highlights some of the major findings in immunology and 
furthermore illustrates the fast-paced environment and continuous discoveries that led to a 
research area of computational and systems immunology. With the technical advancements in 
omic technologies and machine learning algorithms it is now possible to study the immune 
responses at multiple levels with the promise to move from descriptive to predictive models 
of human diseases18,19. This thesis is a descriptive systems immunology approach with the 
primary objective of creating a protein landscape of the hematopoietic system. Secondary, the 
proteomic toolbox was used to identify novel immune response mechanisms that enabled the 
development of novel immunotherapeutic strategies. 
The following section provides an overview of the immune system's major components, with 
an emphasis on T lymphocytes. The final chapter highlights proteomic strategies for studying 
the immune system and concludes with a summary of available immune networks. 
 
 
Organs of the immune system 
The network of immune organs facilitates a regulated immune response allowing the rapid 
production of a large number of immune cells and molecules, which can penetrate almost any 
tissue throughout the body20. Most immune cells arise from the bone marrow and then reside 
in the blood or tissues. For example, T and B lymphocytes mature in the primary immune 
organs (thymus or bone marrow, respectively), where they recombine their immune 
receptors21. Afterwards they migrate to the secondary immune organs, including lymph nodes, 
spleen, Peyer’s patches, the appendix, tonsils, adenoids, and other lymphatic tissue. Because 
of that these cells are often referred to as lymphocytes20. 
Immune cells constantly scan the body for pathogens using the blood and lymphatic system as 
means of transportation. The lymphatic system is a complex network dispersed throughout the 
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whole body, including the central nervous systems22. It consists of thin-walled lymph 
capillaries, which lead to afferent lymph vessels, which in turn connect to the lymph nodes. 
Its vessels are filled with lymph, a clear protein-containing fluid, which is passively moved 
unidirectional by skeletal muscle contractions towards the heart and eventually reenters the 
bloodstream at the junction of the internal jugular and subclavian veins at the base of the right 
side of the neck23. Together with the blood system, the lymphatic system forms an important 
meeting ground for immune cells to initialize an immune response24. 
 
Cells of the immune system 
The cells of the immune system can be roughly categorized into innate or adaptive immune 
cells (Figure 2). While first react more quickly, latter can take a few days to fully develop an 
immune response against an invading pathogen20.  
Mast cells, granulocytes, macrophages, monocytes, dendritic cells and natural killer cells 
form the innate arm of the immune system25. Mast cells are involved in allergic reactions and 
can release granules of histamine and heparin upon pathogen encounter. They also play an 
important role in inflammation and wound healing. Granulocytes are divided into three 
subgroups based on their granule content (neutrophils, basophils, and eosinophils). They are 
relatively short lived and play an important role in the early defense against parasites and 
extracellular bacteria. Their ability to phagocytose invading bacteria induces the release of 
inflammatory cytokines, which causes adjacent blood vessels to dilate and other immune cells 
to migrate towards the inflammation point. In particular, Neutrophils can undergo a suicidal 
extrusion called neutrophil extracellular traps, which create a physical barrier preventing 
pathogens from spreading26. Macrophages (MQ) comprise another phagocytic cells type that 
produce inflammatory cytokines, but unlike neutrophils reside in the tissue and are relatively 
long-lived27. 
Dendritic cells (DCs) are also capable of phagocytosis, but more importantly like MQ can 
activate cells of the adaptive immune system by presenting pathogen peptides on their cell 
surface. Hence, DCs and MQ are called antigen presenting cells (APCs)28. In detail, upon 
encounter of a pathogen, APCs internalize the microbe or its debris and generate peptide 
fragments via the proteasome. These fragments are then shuttled to the cell surface being 
bound to a receptor complex called major histocompatibility complex II (MHC-II). APCs are 
divided into two subclasses. DCs and MQ are professional APCs29. They express co-
stimulatory molecules on their cell surface (e.g. CD80, CD86, and CD40) and, together with 
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the MHC-II can activate naïve T lymphocytes by forming an immunological synapse. Non-
professional APCs like fibroblasts or vascular endothelial cells lack those co-stimulatory 
receptors and can only reactivate memory T lymphocytes30. 
Natural killer (NK) cells form another innate immune cell type but interestingly are more 
closely related to the adaptive immune lymphocytes. Through their specialized receptors, they 
scan the body for infected or tumor cells and once identified release cytotoxic granules that 
kill the target cell. Recent evidence revealed that specific NK subsets can acquire long-lived 
and highly specific memory of a variety of viral and hapten-based antigens20, linking the 
innate arm to the adaptive immune cells31. 
 
 
Figure 2: Innate and adaptive immune cell types. The rapid innate immune response consisting of soluble 
factors (complement proteins) and cellular components (granulocytes, mast cells, macrophages, dendritic cells, 
and natural killer cells) form the first line of defense against pathogens. In contrast the slower developing 
adaptive immune response consists of antibodies, B cells, and CD4 and CD8 T lymphocytes. Natural killer T 
cells and gamma-delta T cells straddle the interface of innate and adaptive immunity, as illustrated by the 
overlap of the two circles (adapted from25). 
 
T and B lymphocytes form the adaptive arm of the immune system. T lymphocytes are 
broadly classified based on their CD8 or CD4 receptor expression in two cytotoxic or helper 
cells, respectively. Upon activation CD8 T lymphocytes secrete cytotoxic granules containing 
granzymes and perforin which induce apoptosis in the target cell32. In contrast, CD4 T 
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lymphocytes upon activation release cytokines that either drive cell-mediated immunity by 
MQs and CD8 T cells or humoral immunity by B lymphocytes. Thus, they are called T helper 
(Th) cells and, depending on their secretory profile, are classified into four major subclasses 
Th1 (IFNg, TNFb), Th2 (IL-4, IL-5, IL-13), Th17 (IL-17), and regulatory T cells (IL-10)33.  
B lymphocytes fight pathogens by secreting large amounts of antibodies after their activation. 
For example, antibody opsonization, where antibodies mark pathogens by binding to a 
specific antigen on their surface, mediates phagocytosis by MQ or neutrophils. Based on their 
location and function, B cells are broadly classified in B1 and B2 lymphocytes. B1 cells are 
the main producers of natural antibodies and can be found in the pleural and peritoneal 
cavities. B2 cells are further divided into marginal zone B cells (MZ B) and conventional 
follicular B cells (FO B)20. While MZ B cells are located in the marginal zone of the spleen 
and take part in the innate immune response, FO B cells reside in the lymphoid follicles of 
secondary lymph organs and play a role in the adaptive immune response34. 
The diversity and hetrogeniety of immune cell subsets is constantly evolving, in particular due 
to high-resolving and single cell technologies. Here, we briefly described only on the main 
subsets, however, due to discoveries of novel secreted molecules or receptors and the use of 




Immune cells use diverse molecules – and in particular cytokines – to communicate with each 
other. They are important messengers involved in autocrine, paracrine, and endocrine 
signaling. Classically, they act on cells by binding to their corresponding extracellular 
receptor thereby regulating maturation, growth, and responsiveness of immune cells and their 
surrounding tissue. Besides immune cells, cytokines can also be secreted by other cells of the 
body like endothelial cells. Typically, cytokines are small proteins of 5-20 kDa in size and 
can be divided into four structural families. First, the four-α-helix bundle family containing 
the interleukin (IL) 2 subfamily, the interferon (IFN) subfamily, and IL-10 subfamily, second 
the IL-1 family, third the IL-17 family, and last the cysteine-knot family36. 
Although the functional categorization of cytokines is challenging as new properties of known 
cytokines are constantly being uncovered, they can be broadly grouped into ILs, lymphokines, 
chemokines, IFNs, and tumor necrosis factor family members20. ILs form the broadest and 
biggest group of cytokines and as the name suggest contains cytokines that act between 
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leukocytes. Lymphokines are produced by lymphocytes. Chemokines are involved in cell 
trafficking and are responsible in attracting cells to the inflammation site. IFNs are classified 
into two groups, type I (IFNa and IFNb) and type II (IFNg), and play a pivotal role in the 
combat of a viral infection or cancer37. Tumor necrosis factor family members are 
transmembrane proteins that are released through proteolytic cleavage and can act as 
cytokines. Their name originates from their ability to inhibit tumor genesis.  
Taken together, cytokines control complex communication networks that play an important 
role in orchestrating innate and adaptive immunity. Due to their potent nature they are 
promising therapeutic targets and have been used in the treatment of cancer and 
autoimmunity38. 
 
Inflammation and the Innate Response 
The first line of defense against invading pathogens is the skin and mucosal membranes, 
which form a physical barrier. In case a pathogen can pass this layer - for example through a 
lesion - the innate immune response gets activated. Here, the complement system starts a 
series of proteolytic cleavages when bound to the pathogen39. It thereby covers the pathogen 
with complement proteins that form multimeric complexes, which in turn kills the pathogen 
by disrupting their membrane. 
In addition, innate immune cells such as MQ, DCs, and neutrophils contribute to the innate 
immune response by continuously scanning their local environment for invading pathogen 
and clearing them by phagocytosis. With their receptors, they can sense pathogen associated 
molecular patterns (PAMPs), like lipopolysaccharide (LPS), single stranded RNA, or 
unmethylated CpG20. Upon binding to PAMPs innate immune cells get activated and start to 
secrete proinflammatory cytokines and IFNs, which attracts more immune cells to the 
inflammation site and also makes nearby cells more resistant to infections40. Besides, PAMPs, 
a second class of intracellular molecules called damage associated molecular patterns can 
activated innate immune cells when released into the extracellular environment41. 
 Sometimes pathogens are killed by the instant actions of the innate immune response, 
however often the response is not strong enough to clear the invading pathogen. In order to 
activate the adaptive immune response, APC transport phagocytosed pathogen debris to the 
lymph node, where they present those pathogen fragments to T and B lymphocytes. Once an 
antigen specific lymphocyte recognizes a specific antigen and receives additional signals 
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through secreted molecules, they become activated and start to proliferate. This marks the 
beginning of the slower but targeted adaptive immune response37. 
 
Immune Activation and the Acquired Response 
While innate immune cells have a broad specificity towards pathogens, adaptive immune cells 
are antigen specific - meaning that only a few cells are specific for any given pathogen 
protein. In order to increase the chance of an APC to interact with its few antigen specific T 
or B lymphocytes, these cells continuously circulate throughout the lymphoid organs. When 
the antigen presenting cell and T cell interact and receive the correct co-stimulatory signals, 
they form an immunological synapse20.  
As previously mentioned, APC break down phagocytosed debris into peptides, which they 
present at their cell surface to T lymphocytes via MHC molecules. There are two different 
types of MHC receptors. While intracellular pathogens are presented through MHC-I, 
extracellular derived proteins will be bound to MHC-II receptors37. DCs are considered the 
most potent cell type for activating naïve T and B cells, because they secret co-stimulatory 
molecules and in addition migrate more efficiently through the lymphatic system. With their 
T cell receptor (TCR), T cells scan the surface of APC. However, the majority of TCR/MHC 
interactions will be of low affinity and will not lead to the activation of the T cell20. Only 
when the TCR-MHC complex forms a stable interaction, which is supported by co receptor-
ligand interactions as well as activation signals from inflammatory cytokines, T cells start 
their activation program. This is marked by the rapid clonal proliferation as well as IL-2 
secretion, which further promotes the proliferation process. As a next step, T cells undergo 
differentiation and depending on which T cell subtype they belong to perform different 
functions to enhance the immune response. CD8 T lymphocytes scan the periphery for 
infected cells by interacting with MHC-I receptors. In case the peptide bound to the MHC-I 
receptor causes a tight interaction with the TCR of the CD8 T cell, it will release cytolytic 
granules that penetrate the target cell32. This strategy clears intracellular pathogens by killing 
infected cells. CD4 T cells, also called helper cells, depending on their activation can 
differentiate into different effector cells. Usually caused by intracellular infections such as 
viruses, APC secrete cytokines like IL-12 and INFg, inducing a type-I T-helper (Th1) cell 
specific response. These helper cells aid in the clearance of a pathogen by activation of CD8 T 
cells. In the presence of IL-4, CD4 T cells activate B cells and induce type-II T helper (Th2) 
responses42. B cells present antigens from digested pathogens at their surface through MHC-II 
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receptors. Once the B cell forms a synapse with an activated CD4 T cell with its cognate T 
cell receptor, it becomes activated and undergoes massive expansion and differentiation. At 
the end the B cell will become a plasma cell that produces a large amount of antibodies that 
are released into the blood stream where they can opsonize invading extracellular pathogens43. 
B cell can further improve the affinity of their immune receptors through selection and 
mutation. Those B cell that carry a BCR with higher affinity to their target pathogen will also 
more efficiently recruit T helper cells and thus receive stronger activation signals. With 
successive rounds of target binding, activation, and mutation, the B cells with higher affinity 
will be selected20,44. 
After pathogens are neutralized by activated lymphocytes, the majority of them will perish 
and only a small proportion will form immunological memory. These memory cells reside 
within in the lymph node and can survive there for many years. Once an infection reoccurs, 
these memory cells react more quickly and can yield protective responses within few days45. 
Due to its huge receptor diversity the adaptive immune system can in principle mount an 
immune response to any possible chemical entity. Intrinsic (clonal deletion and anergy) and 
extrinsic (competitive deletion, immunogenic costimuli) cellular strategy are in place to 
control their activity against components of our own body. However, in few cases the tightly 
regulated development of T and B lymphocytes can lead to self-reactive receptors that cause 
uncontrolled and harmful immune responses known as autoimmune diseases46,47. 
 
 
1.1.2 T lymphocytes 
T lymphocytes are required for the establishment and maintenance of immune response, 
homeostasis, and memory. With their ability to recognize a wide variety of antigens form 
pathogens, tumor, and the environment, they preserve immunological memory and self-
tolerance. They derive from bone marrow progenitors that move to the thymus for maturation, 
selection, and finally circulate the body through the lymphatic system. They are broadly 
classified into three subsets: naive T cells, which can respond to novel antigens, memory T 
cells, which are generated through antigen encounter and maintain long-term immunity, and 
regulatory T cells, which regulate self-tolerance48. Understanding how immunological 
memory is formed is not only important for vaccine development, but also relevant for the 




1.1.2.1 Memory T lymphocytes 
We are constantly exposed to pathogens. The skin and mucosae are the primary entry points 
for pathogens. These either directly drain to local lymph nodes, where they are captured by 
macrophages (MQs) or are taken up by dendritic cells (DCs) and then move to secondary 
lymphoid organs51. DCs activate T cells in secondary lymphoid organs through antigen 
presentation, which triggers their proliferation and differentiation into pathogen dependent 
effector cell populations. In the T cell zone, DCs from a close association with the stromal 
cells of secondary lymphoid organs, such as fibroblastic reticular cells (FRCs)52. FRC 
promote the interaction of T cells with DCs by secreting CCL19 and CCL253. In addition, 
CCL3 and CCL4 produced by activated DCs aids in the attraction of antigen-specific T 
cells54. Once the interactions between DCs and T cells stabilize and T cells receive their 
activating signals, T cells gradually alter their expression of various homing receptors that 
promote the migration to inflamed tissue sites. After pathogen clearance, only an exceedingly 
small fraction of the heterogenous pool of memory cells survives. These memory T cells are 
classified into two distinct subsets55 - central memory T cells (TCM) expressing CCR7 and 
CD62L, and effector memory T cells (TEM) lacking these molecules. TCM can produce IL-2 
and proliferate rapidly, while TEM are less proliferative and contain effector cytokines such 
as IFNg56. TCM predominate in secondary lymphoid organs, while TEM reside preferentially 
in peripheral compartments57,58. Surface molecules further elucidate the functional 
heterogeneity of the memory T cell subsets. For instance, with the chemokine receptors 
CXCR6, CCR3, CRTh2, CXCR3, and CCR4 the TCM and TEM pool can be subdivided into 
Th1 and Th2 cell characteristics59. Memory T cells also differ in their migratory or effector 
functions. For instance, tissue resident memory T cells form another subset that describes 
memory T cells that permanently reside in peripheral tissues after pathogen clearance60,61. The 
diversity of immune cells is important for orchestrating effective defense mechanisms. 
Unconstrained memory T cell trafficking in the peripheral tissues is one important factor to 
protect from reinfections. However, long lived memory T cells often fade over time and 
understanding the mechanisms for protective T cell immunity remains important for better 
vaccine development. 
 
T cell priming and memory generation 
During an infection, naive T cells rapidly proliferate, forming an enormous pool of antigen 
and pathogen-specific cells62. T cell expansion is often proportional to the initial frequency of 
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naive T cell precursors63. However, besides precursor frequency, multiple factors influence 
the production of effector and memory T cells – pathogen type, recruiting of naive T cells64, T 
cell migration, T cell receptor stimulation65 including antigens, enzymes, cytokines and 
chemokines. These factors not only determine cell numbers but also regulate the generation of 
effector versus memory cell populations66,67. For instance, chronic infections with high 
antigen and inflammation levels favor short-lived effector cells than memory cells68. 
Interleukins, such as IL-12 and IL-2, have been shown to promote effector T cell 
production69,70, while IL-10 signaling facilitates memory development71. Expression of 
transcription factors T-bet and Blimp1 lead to an effector type, while Bcl6, Id2, and Id3 is 
required for memory formation72. In addition, metabolic pathways, and nutrient composition 
influence the development of memory T cells (discussed in the next chapter). Together, 
complex signaling networks decide the fate of T cells at different stages during the immune 
response forming different pools of memory T cells. 
 
T cell migration  
T cells are actively migrating through the body. Both, naive T cells and TCM readily migrate 
to lymph nodes searching for antigen before returning to circulation73. Antigens, chemokines, 
and adhesion molecules on high endothelial venules (HEVs), as well as DC-derived signals 
facilitate effector and memory T cell entry into lymph nodes. The initial tethering and rolling 
of cells on the lymph node endothelium is mediated by T cell receptors such as CD62L and 
PSGL-1 binding to peripheral lymph node addressin and P-selectin, respectively56. 
Chemokines, such as CCL21 binding to the T cell receptor CCR7, direct the migration of T 
cells through the endothelium. These interactions activate integrins and allows for firm arrest 
and subsequent diapedesis through HEVs74. 
In non-lymphoid tissues, the vascular endothelium produces a diverse variety of adhesion 
molecules and chemokines that primarily targets effector cells and TEM. Effector T cells can 
migrate into inflamed tissues by downregulating CD62L and CCR7 and upregulating other 
chemokine receptors and adhesion molecules. T cell recruitment to the skin is driven by 
numerous chemokine receptors, including CCR4, CCR10, CCR6, and CCR875, and 
upregulation of E-selectin ligands on T cells that promotes the binding to skin endothelium76. 
In mucosal tissues, such as the small intestine and Peyer's patches, T cells up upregulate 
integrin alpha4beta7 that binds to mucosal addressin cell adhesion molecule-177. In the lung, 
integrin VLA-1 and the chemokine receptors CXCR3 and CCR5 play a critical role in T cell 
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trafficking critical for lung78. Many other chemokine receptors expressed on effector T cells 
(e.g., CXCR6, CCR1, CCR2, and CCR3) probably also play critical roles in tissue-specific 
homing and microenvironmental trafficking inside tissues79. Nonetheless, more research is 
needed to understand the complex network of chemokine receptor, integrin, and selectin 
expression on memory T cells that determine the trafficking into specific tissues56. 
 
1.1.2.2 T lymphocyte metabolism 
The availability of nutrients, growth factor cytokines, as well as key receptor signaling 
pathways control metabolic reprogramming inside the cell. These metabolic pathways affect 
cell differentiation and function80. During development and quiescence, T cells cycle through 
different metabolic states. For instance, activation of the receptor Notch1 maintains cell 
survival and promotes linage commitment81, while T cells migrate from the bone marrow to 
the lymph node, where they rearrange their antigen receptor gene loci to produce functional T 
cell receptors80. Together with CXCR4, phosphatidylinositol 3-kinase (PI3K) gets activated to 
stimulate anabolic metabolism82. Later in the development stage, glucose transporter 
expression increases and through the activation of the mechanistic target of rapamycin 
(mTOR) via PI3K-Akt signaling, glycolytic metabolism is augmented that supports cell 
growth and proliferation83,84. Furthermore, the cytokine IL-7 induces the expression of 
antiapoptotic factor Bcl-285 and therefore also plays an important role in the maintenance of 
survival and linage commitment86. To generate ATP, quiescent T cell primarily consume 
pyruvate via oxidative phosphorylation (OXPHOS) or use fatty acid oxidation (FAO)87. All 
these signals are essential to work in concert to sustain homeostatic proliferation of naive T 
cells88. 
 
Metabolic reprogramming during the life cycle of T cells 
Once naive T cell encounter their specific antigen and co-stimulatory signals are in place, they 
get activated and proliferate in an explosive manner. To accumulate the required biomass, 
their metabolic pathways switch to aerobic glycolysis (Figure 3). Although less efficient than 
OXPHOS in generating ATP, it produces important metabolic intermediates for cell growth 
and proliferation89. For instance, pentose phosphate and serine biosynthesis pathways use 
glucose-6-phosphate or 3-phosphoglycerate to produce precursors for nucleotide and amino 
acid synthesis90. This process is coordinated by several transcription factors and signaling 
pathways. IL-2 and other growth factors promote the switch to glycolysis via nutrient 
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transporter expression and activation of the key metabolic regulator mTOR91,92. In addition, 
transcription factors, c-Myc, estrogen-regulated receptor alpha, and hypoxia inducible factor-
1 alpha induce the expression of genes involved in intermediary metabolism that stimulate the 
clonal expansion of T lymphocytes93–95. Furthermore, different metabolic pathways also 
promote the differentiation of CD4 T lymphocytes. For instance, suppression of mTOR 
augments the production of Tregs upon activation96. While Tregs depend more on the 
oxidation of lipids, Th1, Th2, or Th17 exhibit a strong glycolytic profile via the mTOR 
pathway97. In addition, the two different mTOR complexes regulate the development Th1 and 
Th2 subsets80,98.  
 
 
Figure 3: T cell metabolic programs in resting and activated state. While resting T cells predominately rely 
on oxidative phosphorylation for energy, activated T cells downregulate lipid oxidation and increase and 
glycolysis to produce sufficient biomass for rapid cell growth and proliferation. After the immune response, 
activated T cells metabolically revert and form a small pool of memory T cells (adapted from99). 
 
After pathogen clearance, effector T cells undergo apoptosis and form a small population of 
long-lived memory T cells. This memory formation is also driven by different metabolic 
mechanisms. For instance, metformin promotes the generation of memory T cells after 
infection by activating adenosine monophosphate-activated protein kinase (AMPK)100. 
AMPK suppresses mTOR and thereby promotes FAO101 and the generation of memory T 
cells. Also inhibiting mTOR directly with Rapamycin boots the memory development102. A 
second central characteristic of efficient memory formation is FAO100. It has been shown that 
the number of CD8 memory T cells increases when FAO is enhanced via carnitine 
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palmitoyltransferase 1a103. Together with IL-15 and IL-7, these signals support catabolic 
metabolism and promote mitochondrial biogenesis, giving memory T cell a greater respiratory 
capacity compared to naive or effector T cells. This bioenergetic surplus allows memory T 
cells for a stronger response to secondary infections103,104. However, it remains not completely 
understood what specific role FAO has in the development of memory T cells. 
 
Key metabolic substrates 
As mentioned before, glucose is an important metabolite for T cells80. It is a relevant energy 
source for the generation of biomass and production of activation markers required for 
proliferating T cells105. T cells show impaired cell activation, clonal expansion, and survival 
when deprived from glucose106 or when their glucose transporter Glut1 is deleted107. 
Amino acids are an alternative class of metabolic substrates.  Depending on their metabolic 
requirements, T cells harbor different amino acid concentration during their activation 
cycle108,109.  Many different amino acid transports as well as catabolizing enzymes are being 
discovered that regulate T cell metabolism and function. For instance, the glutamine 
transporter or the transporter Slc7a5, which transports neutral amino acids such as leucine, 
play an important role in effector T cell generation110,111. On the molecular level, leucine can 
activate mTOR via leucyl-tRNA synthetase and consequently, impaired uptake  inhibits 
mTOR112,113. Studies suggest that leucine deficiency has also additional effects on the 
metabolic transcription factor c-Myc109. The importance of leucine in T cell activation was 
further studied by manipulating the cytosolic branched chain aminotransferase, an enzyme 
that can control intracellular leucine concentration114. Furthermore, the alanine serine and 
cysteine transporter system (ASCT2/Slc1a5), is another important glutamine carrier during T 
cell activation. When depleted, glutamine levels are decreased, disbalancing the OXPHOS 
and glucose metabolism115. Arginine metabolism has a well-established role in MQ 
polarization116 and several studies support that extracellular arginine concentrations can also 
influence T cell activation. For instance, depleting arginine impairs aerobic glycolysis117. 
Since substrate availability has a great influence on T cell response, studies have shown that 
antigen presenting cells can regulate extracellular concentrations of amino acids to control T 
cell activation. For instance, DCs can either express multiple amino acid transporters to 




Lipids and fatty acids are other critical substrates in T cell growth, activation, and effector 
function - vital for cell membrane synthesis, energy consumption, and cell signaling. After 
activation, the cellular demand for fatty acids increases and FAO shifts to FAS120. As 
described earlier, mTOR and c-Myc are key coordinators93, but also liver X receptors (LXR) 
and sterol regulatory element-binding proteins (SREBP) are critical to facilitating this 
metabolic shift121. After antigen stimulation, T cells decrease LXR activity and increase the 
SREBPs122. This leads to reduced cholesterol efflux and increased de novo synthesis of fatty 
acids and cholesterol123. Pharmacological interventions in the lipid and cholesterol 
homeostasis of T cells can heavily influence their proliferation capacities121,122. In addition, 
lipid metabolism also plays an important role in T cell differentiation and effector function. 
By inhibiting FAS via acetyl-CoA carboxylase 1, the generation of Th17 is reduced and Tregs 
increased. Furthermore, this inhibition also impaired Th1 and Th2 development124. 
The connection between metabolism and gene regulation in T cells is overly complex125. As 
indicated by the many studies mentioned above, the continuous increase in knowledge of 




1.1.3 Cancer immunotherapy 
The idea to exploit the immune system to treat cancer dates back decades 127,128 and found its 
recent peak by the award of the Nobel Prize in 2018 for the discovery of cancer therapy by 
inhibition of negative immune regulation. Cancer is characterized by dysregulation of cellular 
processes and accumulation of genetic alterations. Such events can cause the expression of 
mutated self-proteins, called neo-antigens, which in turn can lead to their presentation on the 
surface of cancer cells. Thus, cancers can be recognized by the immune system as foreign and 
be targeted by cytotoxic T cells. However, tumors have developed multiple resistance 
mechanism to evade such T cell responses. The delicate balance between the recognition of 
non-self and the prevention of autoimmunity is the current challenge in novel cancer 
immunotherapy strategies129. 
 
The Cancer-Immunity cycle 
The effective killing of tumor cells by the immune system requires distinct checkpoints130. 
First, antigen presenting cells like dendritic cells (DCs) capture neoantigens created by 
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oncogenesis and present these through MHCI or MHCII receptor molecules on their surface. 
To trigger an effective anticancer T cell response, secondary signals such as proinflammatory 
cytokines must be released promoting the presentation of these foreign antigens.  T cells get 
activated when they encounter their corresponding cancer-specific antigen. Eventually, 
activated effector T cells traffic and infiltrate the tumor bed and through their T cell receptor-
MHCI-antigen complex specifically recognize and kill cancer cells. This leads to the release 
of more cancer antigens and increases the magnitude of the anti-cancer response in successive 
cycles. In cancer patients, this cancer-immunity cycle is apprehended by different means.  
 
 
Figure 4: Stimulatory and Inhibitory Factors in the Cancer-Immunity Cycle. The different steps from 
antigen release, antigen presentation, priming and activation, immune cell trafficking, tumor infiltration, cancer 
cell recognition, and cancer cell killing are illustrated and for each step inhibitory (red) and stimulatory (green) 
factors are highlighted (adapted from130). 
 
Either antigens are not detected, antigens are tolerated, T cell do not traffic to the tumor, the 
tumor is not accessible to T cells, or the tumor microenvironment suppresses the effector 
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cells131. Cancer immunotherapy’s main aim is to reinitiate a self-sustaining cycle of cancer 
immunity, without triggering an autoimmune inflammatory response. Thus, it needs finetuned 
treatment strategy to overcome the negative feedback mechanisms of the immune system. 
Ideal treatment strategies are therefore patient-specific and identify the rate-limiting step to 
selectively target the appropriate checkpoints in the cancer-immunity cycle (Figure 4). 
 
Cancer Vaccines 
Like traditional vaccines against viruses, it is possible to immunize patients against cancer via 
tumor antigens132. However, in contrast to vaccines against infectious agents, cancer vaccines 
must, besides other challenges, also break immune tolerance acquired by the tumor to be 
effective133. Accordingly, several hurdles must be overcome to develop a cancer vaccine that 
achieves a potent cytotoxic T cell response. First, appropriate tumor antigens need to be 
identified. To avoid tolerance through antigenic drift, multivalent vaccines need to be 
designed. Sequencing data from tumor tissues can identify mutations or translocation fusions 
and thus predict potential antigens. However, patient and tumor heterogeneity and the 
mechanism that only certain peptides are presented on the surface of DCs, makes such 
predictions difficult134. Affinity purification mass spectrometry techniques135 further improve 
the selection of antigen peptide targets, but even with the correct antigens in hand, the optimal 
delivery to patients remains unknown. To bypass this hurdle, DCs can be targeted directly. 
Because of their professional antigen presentation capabilities, they are also called nature’s 
adjuvants136 and can effectively initiate a T cell immune response. In this strategy, DCs are 
isolated from peripheral blood, loaded with tumor antigens, and then reinfused into the 
patient129,133. These DC-based vaccines have shown initial promise for the treatment of 
castration-resistant prostate cancer137. Even if the ideal vaccine can trigger the maturation of 
DCs and promotes the production of tumor specific cytotoxic T cells, numerous mechanisms 
of immune evasion by the tumor might compromise its effectiveness. Hence, cancer vaccines 
might not be administered alone but in combination with other immunotherapy approaches. 
 
Adoptive cell therapy 
This type of immunotherapy is based on the antitumor properties of lymphocytes to eradicate 
tumor cells. Briefly, lymphocytes are isolated from patient’s blood, lymph node, or tumor 
tissue. Then they are expanded ex vivo and finally reinfused into the patient129. This approach 
produces a large amount of effector cells and thereby circumvents the initial steps in the 
Introduction 
26 
cancer-immunity cycle. One version of this approach employs T cells only from resected 
tumor tissue sites. This mixture of CD4 and CD8 positive T cells, also called tumor-
infiltrating lymphocytes, are tumor-specific and when expanded with a cocktail of cytokines 
prior to reinfusion show an increased anti-tumor activity138. A modification to this method 
depletes the host’s lymphocytes prior to the infusion of tumor-infiltrating lymphocytes. As a 
result, immunosuppressive cells, such as Tregs and myeloid-derived suppressor cells, are 
eliminated in the tumor microenvironment and homeostatic cytokine level increased139. This 
approach has been very successful in the treatment of melanoma patients140. However, 
adoptive cell therapies have obvious disadvantages. For instance, cultivation and expansion of 
tumor-specific lymphocytes is time and cost intensive141. Also, this approach has only shown 
to be effective in the treatment of melanoma patients, explained by the high tumor mutation 
burden in melanomas compared to other cancer types142. In addition, the treatment is 
perceived with safety concerns. Although lymphodepletion enhances the efficacy, it can be 
life-threatening and patient selection is not optimized143. To overcome these limitation two 
major genetic T cell engineering approaches have been developed. First, using viral vector-
based expression systems, T cells are transfected to express T cell receptors specific to tumor-
associated antigens. This approach profits from key improvements in gene transfer efficiency, 
T cell receptor design, and target antigen identification selective for tumor cells144.  However, 
the clinical use has been limited due to significant secondary destruction of healthy tissues 
expressing the same target antigen. The second approach fuses an Ig variable domain to a T 
cell receptor constant domain129. These chimeric antigen receptors omit the need for tumor 
cells to carry a specific antigen, as such engineered T cells can potentially target any surface 
protein through their Ig antibody domain145. This approach is most developed in the treatment 
of B cell malignancies, where the chimeric antigen receptor is targeting the B cell linage 
marker, CD19146. New approaches are being developed to extended to other cancers than 
hematologic malignancies and further to address the toxicity and safety issues. 
 
Immune checkpoint blockade 
As briefly mentioned before, tumors can induce immune tolerance through the expression of 
ligands in the tumor microenvironment that bind to T cells and thereby inhibit their function. 
In general, targeting negative T cell regulators is another immunotherapy approach147. For 
instance, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a receptor expressed on T 
cells that down-regulates initial stages of T cell activation when interacting with its ligands 
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B7.1 and B7.2 expressed on DCs148. Ipilimumab, an antibody against CTLA-4 blocks this 
interaction leading to an increased pool of activated T cells. This approach had been approved 
by the FDA as first-line therapy for melanoma patients with metastatic disease149. However, 
the lack of selectivity regulating T cell activation led to a high percentage of immune related 
adverse events in treated patients150. Nevertheless, this initial success in clinical response 
coined the way to new targets, such as programmed cell death protein 1 (PD-1) signaling151. 
Once PD-1 expressed on T cells interacts with its ligand, programmed death-ligand 1 (PD-
L1), expressed on tumor cells, it inhibits the antitumor response of antigen stimulated T cells 
by blocking the secretion or production of proinflammatory proteins, such as IFNg152. 
Inhibiting the interaction of PD-1 and PD-L1 with antibodies enhanced the T cell response 
and mediated anti-tumor activity153. This approach generated promising results in a variety of 
cancer types154. This suggest, that for many cancers the cancer-immunity cycle is intact until 
the step seven of killing cancer cells. The inhibition by PD-1 seems to be rapidly reversible, 
allowing preexisting anticancer T cells to regain their effector function. In comparison to non-
specific activation of the immune system by CTLA-4, PD-1 inhibition shows favorable 
toxicity and safety profiles155 with significant response rates156. Unfortunately, only a 




As outlined above the cancer-immunity cycle can be inhibited or stimulated at different steps. 
However, single therapy approaches are not as effective as combination therapies that also 
take the patient’s cancer immunological state into account159,160. For instance, disabling the 
immune inhibition in the tumor microenvironment, e.g. using an PD-L1 inhibitor, could 
benefit vaccines that target earlier stages in the cancer-immunity cycle. However, PD-L1 
inhibition might not be the right therapy approach for patients with immune deserted 
tumors161. Approaches that show promising results combine CTLA-4 with PD-1 inhibitors. 
While CTLA-4 enhances the priming and activation of T cells, blocking PD-1 removes the 
inhibition of cancer killing T cells inside the tumor. This two-step approach showed rapid and 
deep response in melanoma patients 162. Furthermore, anti-PD-1 in combination with 
vaccination163,164 or with agents enhancing T cell trafficking and infiltration into the tumor 
bed131,165 emerge as promising strategies for the treatment of cancer. Furthermore, 
conventional therapies such as chemotherapy or radiotherapy, although harmful to the 
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immune system, also benefit antitumor responses by releasing multiple tumor neoantigens166. 
Cyclophosphamide know to deplete Tregs167 or paclitaxel know to eliminate MDSCs168, 
counter immunosuppressive activities. 
 
Biomarkers 
Although immunotherapy has greatly improved therapy options for certain cancer types and 
its development is progressing at an enormous pace, not all patients respond to these novel 
strategies. Patient selection based on molecular tumor characterization is crucial for treatment 
benefit and to avoid treatment-related toxicity. Therefore reliable biomarkers that are able to 
predict the clinical benefit are needed169. For instance, the mutational tumor frequency 
correlates with the clinical response to anti-CTLA-4 therapy in melanoma170 or to PD-1 
inhibitor in NSCLC171 and colon cancer172. In general, it is hypothesized that high mutational 
burden is associated with positive response to immune check point inhibitors for certain 
cancers142,173. In addition, the expression levels of PD-L1 on tumor cells serves as a useful 
biomarker to identify patients that could benefit from such targeted therapies153. However, 
this biomarker is controversially discussed in the literature. It has been shown that patients 
with low PD-L1 expression might still benefit from anti-PD-L1 antibodies162, while patients 
with high PD-L1 expression do not 174. Furthermore, other biomarkers are explored that could 
predict the treatment response to immunotherapy, e.g. tumor infiltrating lymphocytes175, T 
cell exhaustion markers157, or genetic profiles of the tumor microenvironment176. Overall, 
more data from human tumors are necessary to further understand the cancer-immunity cycle 
and to improve cancer therapy response rates. More specific biomarkers will improve clinical 






1.2.1 Proteomic strategies to study the immune system 
Studying the immune system on the level of proteins, requires the measurement of many 
proteins at the same time. Omics-technologies such as mass spectrometry (MS)-based 
proteomics not only allows the characterization of the expression levels of thousands of 
proteins inside immune cells, but also their interaction partners, post-translational 
modifications, and localization177. This versatile toolbox has become an essential part of 
modern systems immunology research and has contributed to many novel mechanisms of the 
immune system178. 
Affinity purification combined with quantitative mass spectrometry-based proteomics (AP-
MS) is a widely used strategy to study protein complexes of signaling pathways or to create 
protein interaction maps of complete cellular proteomes179. Usually, the protein of interest 
serves as bait and through immunoprecipitation interaction partner are retrieved180.  This 
strategy has been applied to many immunological research questions. To highlight a few, with 
AP-MS novel components and regulators of inflammasomes have been discovered. For 
instance, gasderminD181 or NIMA-related kinase 7182 were identified as an important 
mediators in NLRP3 activation. Furthermore, post translational modifications play a pivotal 
role in cellular signaling pathways. Phospho-peptide enrichment methods, such as titanium 
dioxide or immobilized metal ion affinity chromatography, together with tailored peptide 
identification and quantification methods have allowed immunologist to study 
phosphorylation sites on thousands of proteins from small sample amounts183,184. One of the 
most unique affinity MS-based strategy in immunology is the characterization of peptides 
bound to MHC molecules. In this two-step approach, MHC-peptide complexes are isolated 
via immunoaffinity purification and then the bound peptides are eluted for mass spectrometer 
(MS) analysis185,186. This approach has increased the understanding of the immunopeptidome 
dramatically by identifying neoepitopes from primary tumor material187, post translational 
modifications188, and proteasome-generated spliced peptides189. 
MS-based imaging strategies allow the study of cell and protein localizations in complex 
tissue samples. Different imaging methods have been developed that differ in labelling, scan 
mode, and resolution190. While matrix-assisted laser desorption ionization mass spectrometry 
imaging (MALDI-MSI) does not require any antibodies for detection it has the lowest 
resolution compared to other used methods191. Imaging mass cytometry (IMC) analyses 
metal-conjugated antibody-stained tissue samples192. This technique measures up to 50 
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antibodies simultaneously by raster scanning the tissue at 1 µm2 spatial resolution193. The 
third and newest methods, multiplexed ion beam imaging (MIBI), also uses antibodies for 
protein quantification, but due to its novel ion beam can scan the tissue samples multiple 
times with a resolution of 10 nm194. These imaging strategies have been applied to many 
different clinical tissue samples and created astonishing pictures of the heterogeneity of the 
tumor environment192. As imaging is mainly based on static tissue samples, it does not capture 
protein localization dynamics. In addition, image-free proteomics approach have been 
developed to create organellar maps, which can characterize the protein composition of all 
major organelles and can study translocation events of proteins after stimulation195. 
Subcellular proteome analysis is a another commonly used proteomics strategy to study the 
immune system. For instance, intercellular immune cell communication pathways have been 
studied with traditional antibody-based methods such as ELISA focusing on few secreted 
proteins. In contrast, with MS-based proteomic approaches unbiased global secretion patterns 
can be analyzed. This strategy allows the time-resolved investigation of hundreds of secreted 
proteins from primary immune cells196. Furthermore, unconventionally protein section 
through extracellular vesicles, including exosomes, are another subcellular structure ideal for 
proteomic analysis197. These protein-cargo structures are typically isolated via centrifugation, 
affinity purification or filtration-based methods. Using proteomics many different EVs have 
been characterized198 and new protein biomarkers discovered199. 
Cellular and tissue proteomics has been extensively applied to primary immune cells as well 
as diverse cancer tissue samples. Many different methodologies to analyze complete cell 
lysates have matured over the last decades and the common shotgun workflow is discussed in 
the next section. This quantitative proteomic strategy has revealed subset specific pattern 
recognition pathways in mouse dendritic cells (DCs)200. In human DCs, proteome profiling 
found that plasmacytoid DCs only express inflammatory-related proteins at low levels, thus 
unable to secrete pro-inflammatory cytokines201. Not only innate, but also adaptive immune 
cells have been characterized with this strategy. For instance, proteomic analysis revealed 
cytotoxic protein abundance difference in human CD4 T cell subsets202 and the metabolic 
mTOR signaling pathways have been studied in cytotoxic T cells under different inhibitory 
conditions at a depth of almost 7,000 proteins203. Besides cell type resolved complete 
proteome analysis, this workflow has also been successfully applied to cancer tissues for 
biomarker discovery204,205. 
Together, these proteomic strategies have made major contrition to our understanding of the 
immune system. Novel proteomic technologies are on the horizon that will generate more 
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detailed insights of immune cell subsets and their functional difference. However, seamless 
integration with other omic-technologies will play a crucial role to generate even more 
comprehensive pictures of the complex interplay of the different immune cells in time, spatial 
and context-specific manner206. 
 
1.2.2 Quantitative shotgun proteomics workflow 
Quantitative shotgun or bottom-up proteomics describes the quantification of proteins from 
their proteolytic digested peptides. The workflow is divided in several steps from protein 
extraction, digestion, peptide purification, peptide ionization, peptide mass analysis through 
fragmentation, peptide identification and protein quantification (Figure 5). 
 
 
Figure 5: The quantitative shotgun proteomics workflow. a) The different steps from protein extraction, 
digestion, peptide purification, peptide ionization, and peptide mass analysis are displayed. b-c) The peptide and 
subsequent protein identification process is illustrated. d) Quantitative protein abundances derived from peptide 
intensity spectra are used for different data analysis pipelines (adapted from207). 
 
First, proteins are extracted using a lysis buffer that typically contains detergents, followed by 
mechanical breakdowns steps such as sonification. Protease inhibitors are added to protect 
from unspecific proteolysis and cysteine oxidation is avoided by reducing and subsequent 
alkylating substances. The proteins are then digested using proteases with specific cleavage 
motifs. Most commonly, Trypsin and LysC are used for this step, resulting in peptides with 
terminal arginine or lysine amino acids. Finally, the peptide mixtures are cleaned for the 
subsequent MS analysis. Therefore, detergents and other MS interfering substances are often 
removed via filter aided devices208,209. When digesting complex samples such as immune 
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cells, the resulting peptide mixtures are too complex to be directly analyzed by MS. 
Proteomes from these cells can contain more than 100,000 unique peptides210. With reverse-
phase ultrahigh-pressure liquid chromatography the peptides are gradually eluted from the 
hydrophobic column thereby reducing the complexity of the sample. The chromatographic 
resolution is a key element in the shotgun workflow and many parameters, such as column 
material, length, diameter, and temperature, have been optimized to achieve robust and 
reproducible elution profiles211–213. Next, the eluting peptides are ionized and thereby sprayed 
into the mass analyzer via the soft ionization method - electrospray ionization214. This method 
applies high voltage between the column tip and the inlet of the MS, leading to the 
evaporation of the solvent and subsequent release of charged peptide ions into the gas 
phase215. These ions are then analyzed by the mass analyzer. The different analyzers can be 
broadly classified into trap (Ion traps, linear ion trap quadrupole, Fourier transform ion 
cyclotrons, Orbitrap) and beam-based mass analyzer (triple quadrupole, time of flight (TOF)). 
Each of them has their different strengths and weaknesses based on mass resolution, mass 
accuracy, dynamic range, and scan speed216–218. Continuous improvements have made the 
Orbitrap, first introduced in 2000219, a common mass analyzer for analyzing complex peptides 
mixtures from cell lysates220–222. Ions are injected off-center and trapped around a cone 
shaped electrode. By circulating around the central electrode on stable trajectories and 
oscillating along the z-axis, the trapped ions induce an alternating image current that is 
deconvoluted by Fourier transformation to obtain peptide mass spectra223,224. In order to 
clearly identify the different peptide sequences, the peptides are further fragmented. Peptide 
dissociation is induced by collision with an inert gas, which eventually breaks the peptide 
bond. To ensure the efficient fragmentation of the different eluting peptides the collisional 
energy is optimized for a specific peptide charges and mass ranges. In the shotgun proteomic 
workflow two different fragmentation methods are frequently used, higher energy C-trap 
dissociation and collision-induced dissociation, generating addition sequence information of 
the peptide225,226. While many peptides with different amino acid sequence have the same 
MS1 mass, they generate sequence specific MS2 spectra. With the combined information of 
the parent-ion mass (MS1) and its mass fragments (MS2), peptides from complex protein 
mixtures can be accurately identified227. Although current mass spectrometers have an 
extremely high scan speed, the selection and fragmentation of all eluting peptides at a given 
time point is not possible. Therefore, different data acquisition strategies have been developed 
to maximize peptide identification rates228. Single or multi reaction monitoring analyses a pre-
selected specific set of precursor ions. Usually run on triple quadrupole instrument, this 
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targeted approach has a high sensitivity, but is not suitable for complete proteome analysis229. 
Data independent acquisition methods, such as SWATH MS, cycle through the total mass 
range with a specific small mass window and fragmentation all precursor ions. In this 
approach, the direct link between the precursor ion and its fragment ions is lost. The resulting 
complex MS2 spectra are deconvoluted with sample specific peptide fragmentation libraries. 
This approach requires extremely fast scan speeds and therefore is often applied with 
quadrupole TOF instruments230. In contrast, data dependent acquisition (DDA) methods first 
select precursor ions in a survey scan and then select the most abundant peptides for 
fragmentation. Therefore, extensive peptide fragment libraries are not needed, as each 
precursor ion is clearly linked to it MS2 spectra. However, in complex samples not every 
peptide will be selected for fragmentation, leading to higher missing peptide quantifications 
as compared to DDA methods. In the Q Exactive HF, a typical acquisition cycle of one MS1 
and 10 MS2 scans takes only one second221. As the average peptide elution time is greater 
than one second, this approach allows the fragmentation of most peptides. 
 
Protein identification 
One central aspect of the computational proteomics workflow is the identification of proteins 
from the acquired peptide mass spectra. Ideally in DDA, each precursor ion can be precisely 
selected without interference of similar peptides and each fragmentation spectrum is 
sufficiently complete to allow the determination of the exact peptide sequence. In practice, 
however, the interpretation of the mass spectra can be challenging, due to contamination from 
co-isolating precursors or incomplete fragmentation spectra. These challenges are ameliorated 
by statistical algorithms. First, recorded MS2 spectra are matched against theoretical spectra 
derived from a sequence data base of in-silico digested proteins. For instance, the search 
engine Andromeda evaluates the match results with a probability-based scoring model. It 
calculates a probability that the observed number of matches between the calculated and 
measured fragment masses could have occurred by chance231. Although, the matching 
performance depends on robust and high-resolution mass analyzers, computational 
approaches can help to improve the peptide identification rate. To avoid high numbers of false 
positive hits, usually a false discovery rate of 1% is applied that is derived from reversed 
amino acid sequences232. In the final step of protein identification, the peptides are mapped to 
protein sequences. Because of protein splice variants or related protein sequences, some 
identified peptides can be assigned to multiple proteins. One commonly used approach 
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addresses this issue by assigning ambiguous peptides to proteins with the most evidence. 
Furthermore, based on the identified peptides certain proteins cannot be distinguished and are 
therefore grouped. As peptide identification, protein identification typically is also controlled 
by a 1% false discovery rate232,233. 
 
Protein quantification 
To determine the concentration of proteins expressed in the cell, they first need to be 
identified and then quantified. In proteomics different relative and absolute quantification 
methods have been developed. While the former compares protein abundances across 
samples, absolute quantification allows comparisons of protein abundances within a given 
sample. All methods have their strengths and weaknesses234. In the following, label-free 
relative quantification and copy number quantification strategies are further discussed235. 
Relative quantification methods come in two flavors labeled or label-free. For instance, 
labeling approaches incorporate stable-isotope versions of essential amino acids in reference 
cell populations.  While not changing the chemical structure or elution profile of peptides, it 
causes a mass shift that can be detected by the mass analyzer. Common labelling approaches 
include, stable amino acid labeling in cell culture236, isotope-coded affinity tags237, and 
tandem mass tags238. Although, such approaches are usually more accurate, label free 
approaches can be applied to any sample and do not suffer from increased sample 
complexity235. In the beginning, label-free approaches made use of the correlation between 
number of detected mass spectra and protein abundance. For instance, spectral counting 
estimates the abundance of a given protein by the number of recorded MS2 spectra239. 
Another approach uses the number of identified unique peptides, normalized by the 
theoretical observable peptides240. While these methods are relatively easy to implement their 
accuracy does not reach the same level of labeled approaches. More recent label-free 
approaches utilize the high resolution MS1 spectra and consider the intensities profiles of all 
identified peptides to quantify the proteins in a sample. For example, the MaxLFQ algorithms 
overcome many challenges of label free quantification. By introducing “delayed 
normalization” and by extracting the maximum ratio information from peptide signals, these 
algorithms archive protein quantification accuracies comparable to labeled approaches241. 
Absolute quantification approaches offer protein estimates to the level of copy numbers per 
cell. This accurate quantification is often achieve using isotopically labeled spike-in standards 
with known quantities242–244. As these approaches are very cost and labor intensive, other less 
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accurate methods have been developed. For example, the total protein abundance approach 
(TPA) does not require any spike-in standard but estimates protein copy numbers only based 
on peptide intensities, the molecular mass, and the protein amount of the cell245. 
 
1.2.3 Networks of the immune system 
The immune systems can be studied on many different hierarchical levels – genomic, 
transcriptional, translational, cellular signaling process, cell heterogeneity, spatial, 
intercellular, and organismal - each of which forms their own networks. These networks can 
be classified by their types of macromolecules and nature of interactions into genetic, gene 
regulatory, protein-protein interaction, metabolic, and signaling networks. Advances in large-
scale omics-technologies and automated bioinformatic analysis pipelines increased the 
number of high-throughput experiments, creating a wide variety of dataset suitable for 
studying the immune system from a network perspective246. As described in the first chapter, 
depending on the disease context the immune response triggers a dynamic and complex set of 
networks from different hierarchies involving hundreds to thousands different molecular 
players. Although, these networks can be analyzed in increasing detail, deriving biological 
functional conclusions form such large-scale networks remains challenging247. 
 
Intracellular signaling networks 
Transcriptional networks, generated from yeast one-hybrid assays, chromatin 
immunoprecipitation experiments, or transcriptomic measurements, are typically analyzed to 
identify new transcription factors or to predict potential target genes248,249. In the 
immunological context they have been widely applied to decipher the transcriptional circuits 
of innate immune sensors and their ligands. In particular, microarray-based transcriptome 
studies identified ATF3 as a negative regulator in TLR-4-stimulated MQs250 or created time- 
resolved functional modules in blood leukocytes during systemic inflammation251. 
Furthermore, by means of RNAi knockdowns, a time-resolved transcriptional network 
revealed the function of 125 transcription factors and divided the pathogen response of DCs 
into inflammatory and antiviral programs252. In addition, gene regulatory networks have been 
used to characterized cell fate and diversity. Network analysis showed that the transcription 
factors, PU.1 and Gfi1, orchestrate innate and adaptive immune cell fates253 and the variety of 
existing macrophage (MQ) activation states, illustrated by more than 200 transcriptome 
profiles, challenged the M1/M2 polarization model254. Together, network analysis of 
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transcriptional and chromatin immunoprecipitation data has identified many fundamental 
gene-regulatory networks that orchestrate the immune response. Signaling networks in 
immune systems typically represent the information flow from an extracellular receptor down 
to its transcription factor or gene target. Besides proteins, also small chemical compounds can 
transmit signals along signaling cascade. Therefore, their network analysis requires the 
integration of multiple molecular networks, such as gene-regulatory and protein-protein 
interaction networks as well as their perturbations. Often signaling networks are analyzed by 
overlaying experimental perturbation data on existing global molecular networks, identifying 
active or suppressed nodes in the network247. MS-based proteomics has emerged as an ideal 
method for studying signaling networks, as it allows to quantify protein abundances, their 
post-translational modifications, interactions partners, and translation rates177. Integrative 
approaches, combing transcriptomics and proteomics as well as functional perturbation 
assays, have created diverse immune cell signaling networks, from TLR signaling in 
DCs255,256 to viral DNA sensing257, providing immunologist with rich resources for further 
discovery projects. Spatial networks investigate the dynamic relocation of proteins during 
signal transduction. Many innate sensors, such as NLRP3, move to specific compartments 
inside the cell to assemble to new complexes or to bind to effector molecules258. Organellar 
structure as well as protein movement adds another important level to the complex network of 
immune responses. Most described networks so far have analyzed immune cells in response 
to single or few purified receptor ligands. However, functional networks try to capture the 
crosstalk between multiple signaling pathways, that are activated during a natural infection. 
For instance, synergistic inflammatory responses have been discovered in TLR ligand-
stimulated human innate immune cells259. Furthermore, sequential triggering of signaling 
pathways, such as LPS priming for inflammasome activation in MQs260, provides the immune 
system with additional layers of immune regulation . These examples illustrate the importance 
to incorporate multiple levels into immune network analytics.   
 
Intercellular networks 
Effective pathogen eradication requires several different immune cell types to act in concert, 
including cells from other parts of the body. Rather than being isolated entities, immune cells 
maintain a continuous exchange with their surrounding environment, using paracrine and 
endocrine signaling pathways261. These highly coordinated and dynamic intercellular immune 
cell networks add another level of complexity to the numerous intracellular networks of the 
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immune system. Although new single-cell technologies, such as single cell transcriptomics262, 
mass cytometry263 or live cell imaging264, have created maps of immune cell plasticity at 
exceptional depth, the integrated analysis of inter- and intracellular networks monitoring cells 
and their expressed proteins remains challenging and usually focus only on a few network 
levels and cell types. For instance, the immune-body cytokine network, derived from publicly 
available databases, identified a greater interconnectivity between immune cells as compared 
to non-immune cells and linked its three-cell cytokine motif architecture to those of social 
networks265. Using curated receptor-ligand databases combined with transcriptomic data, a 
cell-cell communication map containing 144 human primary cells underlined the highly 
connected and redundant ligand-receptor paths and revealed novel interacting cell type 
pairs266. As with protein localization in intracellular networks, the spatial location of cells in 
intercellular networks promotes effective immune responses. Using sophisticated live cell 
imaging methods to explore the cellular positioning and local intercellular communication 
within murine lymph nodes, identified diverse lymphoid cells in close proximity to MQs 
allowing for a rapid antimicrobial immune response267. A subclass of intercellular networks 
form host-pathogen interaction networks. Several such interaction networks have been created 
and collected in diverse databases268,269. Those networks have shown that both bacteria and 
viruses preferentially target host networks nodes with high connectivity and centrality 
involved in immune defense mechanisms270.  
While we are still a long way from developing detailed multi-layered predictive network 
models of the immune response to complex perturbations such as pathogens, the described 
examples illustrate the great potential systems immunology holds for disease understanding271 







2.1 Social network architecture of human immune 
cells unveiled by quantitative proteomics 
 
2.1.1 Summary 
The immune system is unique in its dynamic interplay and its diverse functions are executed 
by highly specialized cell types. A major goal of immunology research is to understand how 
the context-dependent crosstalk of different cell types and the orchestration of their functions 
enable protection against disease247,261,273,274. The interpretation of immune responses is 
inherently challenging due to its plasticity and its context dependent pathophysiological states 
(Figure 6). At the molecular level, intercellular signals are mostly communicated through 
proteins produced by sending cells that act on receptors of receiving cells. Current approaches 
mainly focused on the characterization of interactions between individual cell types or 
cytokines, which neglect a systemic view of the immune response and hence architecture and 
syntax by which biological messages are exchanged between sometimes distant and mobile 
cell types remain incompletely understood265,275.  
In this study, high-resolution mass-spectrometry- based proteomics was used to characterize 
28 primary human hematopoietic cell populations in steady and activated states at a depth of 
>10,000 proteins in total. This unbiases rich proteome resource recapitulates many well-
known immune cell type functions, but also points to novel cell surface markers that could be 
used for staining and flow sorting. Together with selected secretome measurements and a 
newly developed bioinformatic framework, fundamental intercellular communication 
structures and previously unknown connections between immune cell types were discovered. 
For example, less related lineages tend to have more interactions, than close related lineages 
or antigen presenting cells increased their ligand repertoire once activated moving to the top 
of the intercellular signaling cascade. Together, the findings define a social network 
architecture of immune cells and provide a systems biology reference framework of 
intercellular signaling. The quantitative, high-resolution proteomics immune cell 
compendium, including protein copy numbers, assignments of cell-type-resolved functions, 
intercellular communication structures and pairwise cell- type comparisons, is available via 





Figure 6. The immune system as a multi-layered social network. Immune cells need to fulfill many different 
functions within the body. To successful coordinate their abilities, they need to interacted not only with each 
other but also with any other tissue type of the body. This complex interplay resembles in many ways a social 
network. Novel omic-technologies provide new understandings into the basic architecture of these sophisticated 
communication networks among immune cells (adapted from277). 
 
2.1.2 Contribution 
In this collaborative study with the research group of Prof. Lanzavecchia, I performed the 
immune cell type purification as well as the in vitro assays. David Jarrosay conducted the 
flow sorting of the different cell types. I conducted the mass spectrometry analysis of their 
proteomes and secretomes. I completed the RNA extraction and transcriptome analysis. The 
bioinformatic scripts and analysis were written and run by me. The online R shiny application 
was developed by Daniel Hornburg. The manuscript was written by Felix Meissner, Matthias 
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2.2 L-arginine modulates T cell metabolism and 
enhances survival and anti-tumor activity 
 
2.2.1 Summary 
In light of the successful application of T cell-mediated anticancer therapies, the metabolic 
profiles of the heterogeneous T cell subpopulations have been linked to linage stability and 
functionality278. For instance, moderate glycolysis with increased usage of mitochondrial 
oxidative metabolism promotes cell longevity and supports effective T cell responses against 
pathogens and tumors, whereas T cells with heavy glycolytic metabolism show reduced 
longevity and decreased antitumor response279,280. In addition, nutrient composition can 
greatly influence the behavior of immune cells. In the tumor microenvironment, myeloid-
derived suppressor cells can impair T cell responsiveness by degrading L-arginine281. In 
general, arginine metabolism is important for protein synthesis and produces precursors for 
many metabolites, such as polyamines and nitric oxide, which have strong 
immunomodulatory properties282. 
In this study, the metabolic and proteomic changes of activated naïve CD4 T cells over a 
period of 4 days was investigated with a multi-omic approach. The measurements showed that 
after T cell activation the intracellular L-arginine levels decreased while other downstream 
metabolites like ornithine were increased. When adding L-arginine to the culture medium the 
metabolic regulation of T cells changed, indicated by decreased expression of glycolytic 
enzymes and increased levels of TCA and serine biosynthesis pathway proteins (Figure 7). 
This metabolic shift was further observed through reduced glucose consumption rate and 
increased mitochondrial oxidative phosphorylation. In addition, the effector characteristics of 
T cells in L-arginine rich medium changed indicated by decreased INFg secretion and 
elevated expression of the lymph node homing factor receptor CCR7. Most striking, T cells in 
L-arginine rich medium showed increased survival rate in an IL-2 withdraw assay. 
Mechanistically, these changes were in part mediated by the nuclear proteins, BAZ1B, PSIP1, 
and TSN, as their deletion abrogated some of the arginine induced effects. These proteins 
could function as arginine sensors through conformational changes, however their functional 
role remained unclear. In a translational approach, tumor control and overall survival could be 
improved by transferring T cells cultured in medium supplemented with additional L-
arginine. Moreover, oral administration of L-arginine enhanced T cell-mediated antitumor 
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activity. These findings indicated that L-arginine plays a pivotal role in T cell regulation and 
when available in access, promotes a central memory phenotype with increases T cell 
persistence. These characteristics showed beneficial in adoptive T cell therapy approaches. 
Together this study highlights the importance of metabolic pathways and illustrates that 
boosting T cell metabolism presents a great opportunity to increase effectiveness of antitumor 
therapies. 
 
Figure 7. L-arginine promotes memory T cell formation and antitumor activity. Elevated arginine levels in 
T cells inhibit glucose uptake and promote mitochondrial oxidative metabolism. This metabolic change shifts the 
T cell differentiation towards a memory phenotype with higher survival and anti-tumor activity283. 
 
2.2.2 Contribution 
In this collaborative study with the research group of Prof. Lanzavecchia, I performed the 
time series proteomic measurements and analysis of human CD4 T cells. I contributed to the 
analysis workflow with R programming scripts, e.g. enrichment analysis, protein copy 
number estimation, and differential expression analysis. In particular, Figure 1b, 2c, 
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Supplementary Figure 1a-d, and proteomic method sections. In addition, I performed 
measurements of proteomes of mouse CD4 T cell, proteomes of CD4 T cells without arginine 
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2.3 Functional classification of memory CD8(+) T 
cells by CX3CR1 expression 
 
2.3.1 Summary 
CD8 T lymphocytes play a pivotal role in the clearance of intracellular microorganisms such 
as viruses and intracellular bacteria. To provide the host with long term protection against 
reinfections of the same pathogen, memory T lymphocytes are generated284. Depending on 
their functional, proliferative and trafficking characteristics, initially, memory T cell 
subpopulations were classified into central and effector memory T cells based on their 
lymphoid homing receptors (CD62L and CCR7) and their cytotoxic effector functions55. 
However, this view has been extended with tissue resident memory T cells that do not 
recirculate to the lymph node but possess both effector function and the capacity of self-
renewal285. In addition, T cells with effector function are also required in the lymphoid tissue 
to protect for invading bacteria or viruses267, leading to the question whether functionally 
distinct memory T-cell populations exist among CD62L+ central memory T cells in lymph 
nodes. 
In this study, the fractalkine receptor CX3CR1 was identify as a surface marker that 
differentiates CD8+ T lymphocytes with cytotoxic effector function from those with 
proliferative potential both in human and mice. Using transcriptome and proteome-profiling a 
core gene and protein signature led to the identification of a CX3CR1+CD62Lhi memory T 
cell population with direct effector function. Furthermore, this population resides in the lymph 
node and locates to the subcapsular area where pathogens enter. In patients suffering from 
chronic viral infections, the number of CX3CR1+ memory T lymphocytes correlates with 
control of infection and response to immune therapy. CX3CR1-based functional classification 




In this collaborative effort our main contact partners were Percy Knolle, Jan Böttchner and 
Marc Beyer from the University in Bonn. I performed the proteomic measurements and 
analysis of four different CD8 T lymphocyte subpopulations. Together with Marc Beyer and 
Felix Meissner, I contributed to the integrative analysis of the RNASeq and proteomic data 
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3.1 Towards single cell immune proteomes 
Mass spectrometry (MS)-based proteomics has evolved to a high-throughput technology to 
study complex biological systems177,286. Due to its continuous improvements, it is now 
possible to measure the complete proteome of model organisms such as yeast in just one 
hour287.  Especially, improved sample handing accompanied with the use of high-pressure 
high-performance liquid chromatography considerable improved reproducibility and peptide 
identification rates288. New hardware components of mass spectrometers increased their 
speed, accuracy, and sensitivity216. For instance, new orbitrap analyzer can acquire a survey 
mass spectrum followed by ten fragment spectra in less than one second at a resolution of 
15,000 at m/z 200221,227. In addition, sophisticated bioinformatic programs232 and 
quantification strategies241,  laid the foundation for analyzing complete mammalian 
proteomes289 such as those from human immune cells290. 
This thesis extends the journey of complete, accurate and ubiquitous cell proteomes to the 
immune system291. It demonstrates that proteomics can deliver high quality and deep 
proteome profiles not only form individual immune cells, but also from time-resolved 
immune responses as well as multicellular immune systems. The quantitative shotgun 
proteomics workflow was applied to identify functional difference in CD8 T cell subsets292. 
Furthermore, the human CD4 T cell response was investigated, shedding new light on the 
morphological and functional alterations that occur during the first four days of T cell 
activation. More than 30% of all measured proteins significantly change after 3 days, 
including proteins involved in arginine and proline metabolism293. Finally, this thesis provides 
a proteome atlas containing proteome profiles of 28 distinct human hematopoietic cell types 
at a depth of >10,000 proteins, covering 80% of immune related proteins. A new version of 
the orbitrap mass analyzer provided the last puzzle piece to execute a single shot strategy221, 
which reached average protein quantification rates of 7,500 proteins from primary human 
immune cells using 3h gradient single shot measurements294. 
When viewed in the context of large research consortia such as ImmGen295 or the Human Cell 
Atlas35, which primarily characterize cell types at the gene and transcript level, this thesis and 
other studies296,297 create a desire for these consortia to also develop roadmaps for measuring 
complete proteomes of all human immune cell types. This idea is not unfeasible since new 
technology developments have enabled the first comprehensive datasets of single cell 
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proteome measurements298,299. On the one hand, MS-based imaging technologies can analyze 
single cells on protein level already at high throughput, but rely on labelled antibodies and 
usually are limited to only a few proteins that can be measured in parallel300. On the other 
hand, single-shot MS-based proteomics, has the promise to quantify all proteins in a cell. To 
this end three different approaches are being followed. First, Single-Cell ProtEomics by Mass 
Spectrometry (SCoPE-MS)301 and Improved Boosting to Amplify Signal with Isobaric 
Labeling (iBASIL)302 use isobaric tags to create booster channels to overcome peptide 
detection limits and sample loss. With this approach the proteome heterogeneity of monocyte 
and macrophages cell lines was analyzed covering more than 1,000 single cells at a depth of 
3,000 proteins301.  Second, nanoliter-scale oil-air-droplet (OAD) chip303 or nanodroplet 
processing in one pot for trace samples (nanoPOTS)304 use advanced microfluidic devices to 
reduce sample loss and when coupled to a mass spectrometer can reach single cell resolution. 
Third, the true single cell proteome (T-SCP) pipeline uses a novel trapped ion mobility mass 
spectrometer combined with new acquisition methods and miniaturized sample preparation, 
which allowed the quantification of more than 1,000 proteins in single HeLa cells305. 
Although, these new technologies are in their infancy, they already display great potential to 
capture the vast variety of cellular immune networks at the protein level.  
It is evident that proteomics is a versatile “omic” technology that offers the study of 
biological systems from different angles177 and will continue to push its technological 




3.2 Multi-dimensional immune networks for 
personalized medicine 
This thesis constructed three different immune networks - (1) a functional intracellular 
transcriptome and proteome murine CD8 memory T cell network306, (2) an intracellular and 
time-resolved proteome and metabolome network of the human CD4 T cell immune 
response307, and (3) an intra- and intercellular proteome and secretome network of the human 
hematopoietic system294. 
In the first network, transcriptome and proteome analysis identified a novel protein marker 
that functionally differentiates distinct memory T cell populations. Together with protein 
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cluster enrichment analysis, this new marker distinguishes four functionally different memory 
T cell subsets based on migration and cytotoxic potential, leading to a new memory T cell 
population with effector functions and the ability to migrate to the subcapsular sinus of lymph 
nodes. In the second network, the proteomic and metabolic changes during T cell activation 
were investigated. Integrative metabolic network analysis revealed that T cells heavily 
consume L-arginine and convert it to downstream metabolites. Perturbation of the metabolic 
network by providing additional L-arginine resulted in a shift from glycolysis to OXPHOS 
and an increased numbers of T cells with a central memory phenotype. Global protein-
metabolite interaction network analysis was conducted to further elucidate L-arginine 
mediated functional changes in T cells. Moreover, this network study discovered that T cells 
with elevated L-arginine levels exhibit enhanced survival and anti-tumor activity. The third 
network aimed to conduct a global assessment of the immune system by measuring the 
proteomes of all major human hematopoietic immune cells in their native and selected 
activated states. It reached 70% coverage for all immune-relevant signaling molecules 
including transcription factors, adaptor molecules, cell surface receptors, and secreted 
molecules, making it the most comprehensive immune proteome resource to date. Together 
with selected secretome data and bioinformatic algorithms, an immune cell network based on 
receptor-ligand and receptor-receptor interaction data was constructed. Containing more than 
150,000 edges, this cell communication network exceeded the scientific literature knowledge 
network obtained from natural language processing and discovered previously unknown 
outgoing and ingoing connections. In addition, the network architecture revealed that immune 
cell signaling is more diverse inter- than intracellularly in comparison with other organs and 
that antigen-presenting cells increase, while cytotoxic cells decrease their hierarchy height 
upon activation. Furthermore, the network was extended to other organs and tissues of the 
body and found that myeloid immune cells establish more connections with non-immune 
tissues than lymphoid immune cells. Together, this cell-cell network highlights the different 
communication structures between myeloid and lymphoid immune cells on the level of 
proteins and provides a snapshot of cell-type and context-dependent secretion patterns of 
innate immune cells.  
These described networks contribute to the greater picture of network medicine. For instance, 
understanding functional differences of T memory sub populations will enhance our 
understanding of immune protection and enable improved immunotherapies such as vaccines. 
Manipulating T cell fitness by metabolic perturbation can be beneficial for adaptive T cell 
therapies. Finally, global networks such as the hematopoietic proteome network can serve as a 
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reference map for future perturbation studies to identify disease specific network nodes or 
edges that can be targeted by established immune therapies. In general, diverse network 
medicine techniques have led to some central biological findings. The human disease network 
constructed from publicly available disease repositories provided a global view of the 
relationship between disorders and their disease genes308. This approach allowed to study all 
human disease at ones and highlights that most disease genes are non-essential genes and 
constitute nodes at the network periphery271. Using protein-protein interactions maps and 
mathematical algorithms diseases relationships could be explained by overlapping disease 
network modules309. Furthermore, disease-gene networks extended to disease-drug networks 
allowed the prediction of adverse events and therapeutic effects for drug repurposing using 
network proximity measures310. 
While personalized medicine is most advanced in the field of oncology, it still faces many 
challenges to be universally applied in clinical practice311. One puzzle piece includes the 
interpretation of large “omic” data sets and the development of algorithms that can stratify 
patient groups based on biomarkers and are able to recommend treatment strategies from such 
multi-layered networks206. Based on the success stories of immunotherapies130, it is evident 
that the immune system plays a fundamental role in many diseases and disorders. Thus, 
systems-immunology approaches, such as those discussed in this thesis, are only beginning to 
improve the main immunological metrics used in medicine312. It will be fascinating to see 
how the many areas of expertise - from unique human tissue models313 to innovative data 









AMPK adenosine monophosphate-activated protein kinase 
APC antigen presenting cell 
AP-MS affinity purification followed by mass spectrometry 
CTLA-4 cytotoxic T-lymphocyte-associated protein 4 
DC dendritic cell 
DDA data dependent acquisition 
FAO fatty acid oxidation 
FO B follicular B cells 
FRC fibroblastic reticular cells 
HEV high endothelial venules 
IFN  interferon   
IL interleukin 
LPS lipopolysaccharide 
LXR liver X receptors 
MALDI  matrix-assisted laser desorption ionization 
MHC histocompatibility complex  
MQ macrophage 
MS mass spectrometry/mass spectrometer 
mTOR mechanistic target of rapamycin 
MZ B marginal zone B cells 
NK natural killer 
OXPHOS oxidative phosphorylation 
PAMP pathogen associated molecular pattern 
PD-1 programmed cell death protein 1 
PD-L1 programmed death-ligand 1 
PI3K phosphatidylinositol 3-kinase 
SREBP sterol regulatory element-binding proteins 
TCM central memory T cells 
TCR T cell receptor 




TNF tumor necrosis factor 
TOF  time of flight 
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